Asia-Pacific Ablation Devices Market - Growth, Trends, and Forecasts (2023-2028)

The Asia-Pacific Ablation Devices Market is expected to register a CAGR of nearly 7.6% during the forecast period.

The COVID-19 pandemic had a significant impact on the market initially. Due to the lockdown conditions imposed in various Asian countries, surgical procedures reduced considerably including ablation procedures. For instance, according to an article published by the Journal of Clinical Medicine in October 2022, a study was conducted in China which showed that the COVID-19 pandemic had a significant impact on the clinical practice patterns of atrial fibrillation and the catheter ablation and percutaneous left atrial appendage occlusion procedures were significantly reduced. Hence, the COVID-19 pandemic had a significant impact on the market initially. However, as the pandemic has currently subsided, the ablation procedures are expected to take place normally, leading to stable growth of the studied market.

Rising incidences of diseases such as cancer and cardiac ailments are expected to boost the demand for ablation procedures. The technological advancements to design high-end products and growing demand for treatment procedures, which are minimally invasive are also expected to boost the ablation technologies market. Furthermore, the ageing population having a higher risk of target diseases is another vital factor driving the demand for ablation devices.

Japan has a fast ageing population. For instance, according to the data from the 2022 White Paper on Ageing Society, published by the Cabinet Office of Japan, it is estimated that Japan's population aged 65 and over stands at just over 36.21 million in 2021, accounting for 28.9% of the total population. As the geriatric population is expected to increase in coming years who are more prone to chronic diseases such as cancer, cardiovascular diseases, and urinary disorders which are expected to increase the ablation procedures in near future which shows a positive impact on the market.

Furthermore, government initiatives to treat various diseases are also expected to enhance the adoption of ablation devices. For instance, in May 2022, MoHFW of India proposed to increase the number of cataract surgeries to be carried progressively across the country in the financial year 2022-23 to 7.5 million, 9 million in 2023-24, and 10.5 million in 2024-25: amounting to a total of 27 million of surgeries in the next three years.

Moreover, product launches by various market players are also expected to increase market growth. For instance, in November 2021, Medtronic India launched the Arctic Front Cardiac Cryoablation Catheter for the treatment of atrial fibrillation in India.

Therefore, rising prevalence of cancer and other chronic diseases, increasing product launches, and rising geriatric population is expected to enhance the growth of the market over the forecast period. However, high cost of devices, lack of awareness, and stringent regulations are some of the market challenges which is expected to hinder the market growth.

Asia-Pacific Ablation Devices Market Trends

Cancer Treatment Segment is Expected to Hold Significant Market Share Over the Forecast Period

Ablation devices are being increasingly used for the treatment of cancer. Tumor ablation devices have been widely used as it helps in effectively removing a tumor. The increasing prevalence of Cancer in the Asia-Pacific region and the rising geriatric population associated with the increasing incidence of cancer are the major factors driving the growth of the segment.

The increasing prevalence of cancer is a major factor driving the growth of the segment. For instance, according to the data published by National Cancer Center Japan in June 2022, an estimated 1,019,000 new cases of cancer are expected in Japan in 2022, out of which 158,200 new cases of colon/rectum cancer, 132,100 cases of stomach cancer, 128,800 cases of lung/trachea cancer, 96,400 cases of prostate cancer, and 95,000 cases of breast cancer are expected.

Furthermore, according to a report published by the ICMR-National Centre for Disease Informatics and Research in 2021, Leukemia accounted for nearly half of all childhood cancers in both genders in the 0-14 years age group in India, it had a prevalence of 46.4% in boys and 44.3% in girls in 2021. The other common childhood cancer in boys was found to be lymphoma (16.4%), while in girls, it was a malignant bone tumor (8.9%).

Moreover, according to the data updated by the Australian Institute of Health and Welfare in October 2022, it is estimated that around 162,000 new cases of cancer will be diagnosed in Australia during 2022, and 158,350 new cases of cancer were reported in 2021. Similarly, according to a report published by NCBI in March 2022, it is estimated that 274,488 new cancer cases and 81,277 cancer deaths are going to occur in South Korea in 2022. The most common cancer types are expected to be thyroid cancer, followed by lung cancer, colon and rectum cancer, breast cancer, and stomach cancer. These five types of cancer are expected to represent half of the overall burden of cancer in South Korea.

Thus, owing to the increasing prevalence of cancer and the increasing geriatric population, the segment is expected to witness a high growth rate over the forecast period.

China is Expected to Hold Significant Market Share Over the Forecast Period

China is expected to hold a significant share of the market due to the increasing prevalence of ablation surgery requiring diseases such as cancer, atrial fibrillation, and cataract among others. Moreover, the rising geriatric population and the increasing product launches in the country are also expected to boost the market growth.

The increasing prevalence of cancer in the country is a major factor driving the adoption of ablation devices. For instance, as per the report published by the Chinese Medical Journal in March 2022, China is experiencing a greater incidence of cancers. In 2022 it is expected that there will be approximately 4,820,000 new cancer cases in China, in which the most common is lung cancer.

Furthermore, the rising prevalence of diseases such as atrial fibrillation and cataract are also enhancing the market growth. For instance, according to an article published by the Lancet Regional Health in June 2022, a study was conducted in China which showed that the prevalence of atrial fibrillation was 1.6% in the Chinese adult population and it increased with age, and older age, male sex, and cardiovascular disease were some of the factors associated with atrial fibrillation. Similarly, according to an article published by the International Journal of Ophthalmology in January 2022, a study was conducted in China which showed that the overall prevalence of cataracts in Chinese people over 50 years old was 27.45%. Thus, with the rising prevalence of diseases such as atrial fibillation and catracts in China, the usage of ablation devices is expected to increase, as ablation procedures is a preferred treatment option for these diseases.

Hence, due to the abovementioned factors such as the rising prevalence of ablation surgery requiring diseases and the rising geratric population is expected to drive the grwoth of the market in the country.

Asia-Pacific Ablation Devices Market Competitor Analysis

The Asia-Pacific ablation devices market is moderately competitive and consists of a few major players. Companies like Abbott, AtriCure, Inc., Boston Scientific Corporation, Conmed Corporation, Johnson and Johnson, Medtronic PLC, Olympus Corporation, and Smith & Nephew PLC, among others, hold a substantial market share in the Asia-Pacific Ablation Devices Market.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.